NASDAQ:ONC BeOne Medicines (ONC) Stock Price, News & Analysis $350.84 -2.62 (-0.74%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$350.84 0.00 (0.00%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About BeOne Medicines Stock (NASDAQ:ONC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BeOne Medicines alerts:Sign Up Key Stats Today's Range$348.76▼$354.0550-Day Range$303.96▼$376.8652-Week Range$253.95▼$385.22Volume438,376 shsAverage Volume327,201 shsMarket Capitalization$38.52 billionP/E Ratio61.77Dividend YieldN/APrice Target$402.71Consensus RatingBuy Company Overview BeOne Medicines Ltd. is a global biotechnology company focused on the discovery, development and commercialization of medicines for cancer and other serious diseases. The company works across research, clinical development, manufacturing and commercialization, with the goal of expanding access to innovative treatments in markets around the world. BeOne’s commercial portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat certain B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy approved in multiple markets for several cancer indications. The company also maintains a broad oncology pipeline spanning hematologic cancers and solid tumors, including internally developed and partnered programs. Founded in 2010 as BeiGene, the company adopted the name BeOne Medicines in 2025 to reflect its global focus. BeOne serves patients and healthcare providers in the United States, China, Europe and other international markets. John V. Oyler is the company’s co-founder, chairman and chief executive officer.AI Generated. May Contain Errors. Read More BeOne Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreONC MarketRank™: BeOne Medicines scored higher than 70% of companies evaluated by MarketBeat, and ranked 203rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingBeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBeOne Medicines has a consensus price target of $402.71, representing about 14.8% upside from its current price of $350.84.Amount of Analyst CoverageBeOne Medicines has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BeOne Medicines' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth54.71% Earnings GrowthEarnings for BeOne Medicines are expected to grow by 54.71% in the coming year, from $8.81 to $13.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BeOne Medicines is 61.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.67.Price to Earnings Ratio vs. SectorThe P/E ratio of BeOne Medicines is 61.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.49.Price to Book Value per Share RatioBeOne Medicines has a P/B Ratio of 8.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.38% of the float of BeOne Medicines has been sold short.Short Interest Ratio / Days to CoverBeOne Medicines has a short interest ratio ("days to cover") of 4.16.Change versus previous monthShort interest in BeOne Medicines has recently increased by 11.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeOne Medicines does not currently pay a dividend.Dividend GrowthBeOne Medicines does not have a long track record of dividend growth. News and Social Media1.6 / 5News SentimentN/A News SentimentBeOne Medicines has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for BeOne Medicines this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $200,919,444.00 in company stock.Percentage Held by Insiders6.19% of the stock of BeOne Medicines is held by insiders.Percentage Held by Institutions48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BeOne Medicines' insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeOne Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONC Stock News HeadlinesBeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comInsider Selling: BeOne Medicines (NASDAQ:ONC) Insider Sells $13,365,991.70 in StockSeptember 11, 2026 | insidertrades.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.September 20 at 1:00 AM | Paradigm Press (Ad)The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring DealSeptember 5, 2026 | finance.yahoo.comInsider Selling: BeOne Medicines (NASDAQ:ONC) Insider Sells 132 Shares of StockSeptember 4, 2026 | insidertrades.comBeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare ConferenceSeptember 1, 2026 | finance.yahoo.comBeOne Medicines Reaches US Accord on Drug Access, Domestic ManufacturingAugust 31, 2026 | finance.yahoo.comBeOne Medicines (NASDAQ:ONC) COO Sells 280 SharesAugust 28, 2026 | insidertrades.comSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? BeOne Medicines' stock was trading at $303.81 at the start of the year. Since then, ONC stock has increased by 15.5% and is now trading at $350.84. How were BeOne Medicines' earnings last quarter? BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) announced its quarterly earnings results on Wednesday, August, 5th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.40 by $0.65. The business had revenue of $1.71 billion for the quarter, compared to analysts' expectations of $1.66 billion. BeOne Medicines had a trailing twelve-month return on equity of 14.23% and a net margin of 10.70%. Read the conference call transcript. When did BeOne Medicines IPO? BeOne Medicines (ONC) raised $152 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 6,600,000 shares at a price of $22.00-$24.00 per share. Who are BeOne Medicines' major shareholders? Top institutional shareholders of BeOne Medicines include Baird Financial Group Inc. (0.34%), Squarepoint Ops LLC (0.07%), Wellington Management Group LLP (0.02%) and Engineers Gate Manager LP (0.01%). Insiders that own company stock include Bros Advisors Lp Baker, John Oyler, Xiaodong Wang, Chan Henry Lee, Xiaobin Wu, Titus B Ball, Margaret Dugan, Lai Wang, Lai Wang, Corazon (Corsee) D Sanders, Corazon (Corsee) D Sanders, Alessandro Riva and Aaron Rosenberg. View institutional ownership trends. How do I buy shares of BeOne Medicines? Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/05/2026Today9/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ONC's financial health is in the Green zone, according to TradeSmith. ONC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ONC Previous SymbolNASDAQ:ONC CIK1651308 Webbeonemedicines.com Phone13459494123FaxN/AEmployees12,000Year FoundedN/APrice Target and Rating Average Price Target for BeOne Medicines$402.71 High Price Target$454.00 Low Price Target$290.00 Potential Upside/Downside+14.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$5.68 Trailing P/E Ratio61.77 Forward P/E Ratio39.82 P/E GrowthN/ANet Income$286.93 million Net Margins10.70% Pretax Margin14.16% Return on Equity14.23% Return on Assets7.82% Debt Debt-to-Equity Ratio0.17 Current Ratio3.40 Quick Ratio3.06 Sales & Book Value Annual Sales$5.34 billion Price / Sales7.21 Cash Flow$3.91 per share Price / Cash Flow89.76 Book Value$39.77 per share Price / Book8.82Miscellaneous Outstanding Shares109,790,000Free Float102,991,000Market Cap$38.52 billion OptionableN/A Beta0.51 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ONC) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our PartnersGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredWhat Elon Musk did in June 2024In June 2024, Elon Musk faced a problem every AI company was about to hit — how to power a massive AI computer...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
